Market Spotlight: Opioid-Induced Constipation

  • ID: 4533472
  • Report
  • 23 pages
  • Datamonitor Healthcare
1 of 4

This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

  • The approved drugs in the OIC space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also available in subcutaneous formulation.
  • The majority of industry-sponsored drugs in active clinical development for OIC are in Phase II, with only one drug in Phase III. Therapies in mid-to-late-stage development for OIC focus on targets such as opioid receptors and guanylyl cyclase c receptor. All of the pipeline drugs are administered via the oral route.
  • A Committee for Medicinal Products for Human Use (CHMP) opinion for Symproic is the only high-impact upcoming event in the OIC space.
  • There was only one licensing agreement involving OIC drugs during 2013-17.
Note: Product cover images may vary from those shown
2 of 4

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Management of OIC with laxatives
  • Management of OIC with opioid antagonists
  • Management of OIC with Amitiza, a secretagogue chloride channel activator

EPIDEMIOLOGY

  • Recent Prevalence Studies
  • Challenges

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Purdue Highlights Convenience Of New Opioid-Induced Constipation Drug Symproic
  • Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

BIBLIOGRAPHY

  • Prescription Information

APPENDIX

List of Figures
Figure 1: Overview of pipeline drugs for opioid-induced constipation in the US
Figure 2: Pipeline drugs for opioid-induced constipation, by company
Figure 3: Pipeline drugs for opioid-induced constipation, by drug type
Figure 4: Pipeline drugs for opioid-induced constipation, by classifications
Figure 5: Key upcoming events in opioid-induced constipation
Figure 6: Licensing and asset acquisition deals in opioid-induced constipation, 2013-18
Figure 7: Parent patents in opioid-induced constipation

List of Tables
Table 1: Marketed drugs for opioid-induced constipation
Table 2: Approvals by country for opioid-induced constipation
Table 3: Pipeline drugs for opioid-induced constipation in the US
Table 4: Historical global sales, by drug ($m), 2012-16
Table 5: Forecasted global sales, by drug ($m), 2017-22

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll